Rijavec 2010.

Methods	Randomized phase II trial Eligible patients Stage IIIB (wet)/IV or relapsed NSCLC ≥ 70 years of age Chemotherapy‐naive Unfit for bolus platinum administration ECOG PS: 0 to 2 Exclusion criteria not presented
Participants	D arm: not informed DG arm: not informed Demographics for study population: 75 randomly assigned, 69 participants (ITT population), median age 75 years (range 70 to 82)
Interventions	D arm: docetaxel 35 mg/m2 i.v. infusion on days 1, 8, and 15, every 4 weeks DG arm: docetaxel 35 mg/m2 i.v. infusion and gemcitabine 800 mg/m2 i.v. infusion on days 1, 8, and 15, every 4 weeks
Outcomes	Primary outcome Response rate (according to RECIST) ‐ study planned to detect a better regimen for evaluation in further studies, defined as ≥ 8 objective responses required to select a regimen Secondary outcomes Toxicity Time‐to‐progression (TTP) Survival
Notes	Study prematurely stopped because of slow accrual
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	No information on random sequence generation
Allocation concealment (selection bias)	Unclear risk	No information on allocation concealment
Blinding of outcome assessment (detection bias) OS and 1y OS rate outcome	Unclear risk	No information on blinding of outcome assessors. Study considered to have unclear impact on mortality outcomes
Blinding of outcome assessment (detection bias) Other outcomes	Unclear risk	No information on blinding of assessors for other outcomes
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	No information for attrition bias analysis
Selective reporting (reporting bias)	High risk	Results presented in abstract form only. Characteristics of included patients and toxicity partially presented
Other bias	High risk	Trial was stopped prematurely because of slow accrual